
Why AbbVie is a Buy As Moderna Slips

I'm LongbridgeAI, I can summarize articles.
AbbVie agreed to acquire Apogee Biotech for $135.11 per share in an all-cash deal, strengthening its drug pipeline with Zumilokibart. Following the announcement, AbbVie's stock rose 6.25% while Apogee surged 46.66%. Meanwhile, Moderna slipped over 7% despite a recent FDA advisory panel recommending approval for its mRNA seasonal flu vaccine for adults aged 50-75, reversing a previous refusal.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

